NYU LANGONE HEALTH
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1841-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.nyulangone.org
Clinical Trials
1.3k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1109 trials with phase data)• Click on a phase to view related trials
The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial
- Conditions
- End Stage Kidney Disease
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 120
- Registration Number
- NCT07051447
Perceptual Adaptation Following Cochlear Implantation (Aim 3a)
- Conditions
- Sensorineural Hearing LossCochlear ImplantationPerceptual Adaptation
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 22
- Registration Number
- NCT07039435
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study
- Conditions
- Genitourinary Syndrome of Menopause (GSM)
- Interventions
- Drug: Vaginal estrogen tabletDevice: Via Solv Wellness (Hyaluronic Acid Therapy)
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 196
- Registration Number
- NCT07038070
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Extra-cochlear Electrode Placement at the Post-auricular Vagus Nerve in Cochlear Implantation
- Conditions
- Hearing Loss
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 12
- Registration Number
- NCT07011927
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Care in Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 386
- Registration Number
- NCT07011914
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 263
- Next
News
Experimental CoQ10 Precursor Treatment Shows Dramatic Results in 8-Year-Old with Rare Fatal Disease
An 8-year-old boy with HPDL deficiency, a rare mitochondrial disease causing paralysis and often death, showed dramatic improvement after receiving an experimental treatment with 4-hydroxybenzoate (4-HB).
Novel Bispecific Antibody Shows Promise for Autoimmune Disease Treatment in Preclinical Studies
Researchers at NYU Langone Health developed a bispecific antibody called BiTS that targets both T cell receptors and LAG-3 checkpoints to selectively suppress autoimmune T cells.
Mitochondrial DNA Variant Predicts Immunotherapy Resistance in Metastatic Melanoma
Researchers analyzed genetic material from 1,225 metastatic melanoma patients and identified that those with mitochondrial haplogroup T (HG-T) were 3.46 times less likely to respond to checkpoint inhibitor therapy.
URO-1's SUREcore Biopsy System Shows Significant Improvement in Prostate Cancer Diagnostic Accuracy
URO-1's SUREcore biopsy needle demonstrated 92% targeting accuracy compared to 36% for standard needles, representing a major advancement in prostate cancer diagnostics.
ctDNA Monitoring Shows Promise for Predicting Melanoma Recurrence After Surgery
Circulating tumor DNA (ctDNA) monitoring can reliably identify minimal residual disease in patients with resected stage III melanoma, predicting high risk of early recurrence even when patients appear disease-free by radiographic measures.
Ultra-Rapid Genetic Test Revolutionizes Brain Cancer Surgery with Real-Time Tumor Detection
A new Ultra-Rapid droplet digital PCR test can detect brain cancer cells in tissue samples within 15 minutes, providing surgeons with real-time feedback during operations.
BRCA2 Mechanism Reveals Why PARP Inhibitors Work in Only Some Cancer Patients
NYU Langone researchers have discovered that BRCA2 acts as a molecular shield preventing PARP1 from binding to DNA damage sites, explaining why PARP inhibitors are effective only in certain cancer patients.
Nutrition's Critical Role in Cancer Care: From Prevention to Survivorship
Nutrition plays a vital role throughout the cancer journey, with different dietary strategies needed during active treatment versus survivorship and prevention phases.
GLP-1 Agonists Show Significant Benefits for Kidney Transplant Recipients with Type 2 Diabetes
• A landmark study by NYU Langone Health reveals kidney transplant recipients with type 2 diabetes who take GLP-1 agonists experience 49% lower risk of organ failure and 31% reduced mortality within five years. • While the anti-obesity medications demonstrated substantial benefits, researchers observed a 49% increased risk of diabetic retinopathy, highlighting the need for careful eye health monitoring in these patients. • The comprehensive analysis of 18,016 kidney transplant recipients provides the strongest evidence to date supporting GLP-1 agonists as safe and effective tools for managing diabetes in transplant patients.
VAPOR 2 Trial Completes Enrollment: Testing Novel Water Vapor Ablation Device for Prostate Cancer
Francis Medical has successfully completed enrollment of 235 patients across 26 US sites in the pivotal VAPOR 2 trial, evaluating the Vanquish Water Vapor Ablation device for intermediate-risk prostate cancer.